STADAPHARM v Novartis (CFI, 3 February 2025)
| Date | 3 February 2025 |
|---|---|
| Court | CFI |
| Division | Milan (IT) Central Division- Section |
| Type of action | Application RoP262.1 (b) |
| Case number(s) | UPC_CFI_698/2024 |
| Registry reference | UPC_CFI_698/2024 · App_68658/2024 |
| Parties | STADAPHARM GmbH v. ACCORD HEALTHCARE B.V., ACCORD HEALTHCARE S.L.U., ACCORD HEALTHCARE LIMITED, Novartis AG |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By an order of 3 February 2025 (UPC_CFI_698/2024, ORD_68703/2024), the Milan Central Division (Judges Postiglione, presiding and rapporteur, Knijff and Werner) dismissed the request by STADAPHARM, a non-party, for access to the file in the action for a declaration of non-infringement brought by Accord Healthcare against Novartis on EP 2 501 384. Novartis had obtained provisional measures in Germany against STADAPHARM on the same patent, which were under appeal. The order matters for competitors in parallel litigation: access under Rule 262.1(b) cannot be used as a tactical tool against the proprietor.
Question
Can a competitor engaged in parallel national litigation obtain access to the pleadings in a UPC non-infringement action, and are written pleadings without an electronic signature valid?
Decision
Novartis’s pleadings were valid: Rule 4.1 does not require an electronic signature where the filing is unequivocally traceable to the lawyer (paragraph 6). Access was refused: only Accord’s documents were on file at the date of the request, and STADAPHARM itself described them as of no use (paragraph 7). Balancing against the integrity of proceedings weighed against access sought to expose Novartis’s defence and influence the German appeal (paragraphs 8 to 14). There was no risk of irreconcilable decisions between a non-infringement ruling and provisional measures (paragraph 15). Absent a decision on the merits, no costs order was made under Rule 150 (paragraph 16).
Key points for practice
- A request for access covers only the documents on file at the date it is made.
- Practical point: a non-party in parallel litigation with the proprietor must show an interest distinct from its own dispute, seeking a tactical advantage defeats access.
Provisions applied
- Agreement on a Unified Patent Court
- Art. 10, 44, 45 and 73(2)(b)
- Rules of Procedure
- Rules 4.1, 150, 220.2, 224.1(b), 262, 262A and 264
- Case law cited
- Court of Appeal, 10 April 2024, Ocado v AutoStore (UPC_CoA_404/2023), Court of Appeal, Abbott v Sibio (UPC_CoA_480/2024 and UPC_CoA_481/2024), Nordic-Baltic Regional Division (UPC_CFI_8/2023), Milan Central Division (UPC_CFI_380/2024), Paris Central Division (UPC_CFI_412/2023)
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Written procedure (UPC), Confidentiality club.
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- defendantNovartis AG11 decisions in the corpusFollow this party
- claimantSTADAPHARM GmbH3 decisions in the corpusFollow this party
- defendantACCORD HEALTHCARE S.L.U3 decisions in the corpusFollow this party
- defendantACCORD HEALTHCARE LIMITED5 decisions in the corpusFollow this party
- defendantACCORD HEALTHCARE B.V.4 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Application RoP262.1 (b)
- Outcome (Dhenne Avocats summary)
- La section de Milan de la division centrale rejette la demande d'accès de STADAPHARM, faute d'intérêt propre et en raison du risque de pression sur Novartis, et valide les écritures de celle-ci.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 2 501 384mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- STADAPHARM v ACCORD HEALTHCARE (CFI, 3 February 2025) cited in this record
- Ocado Innovation v Autostore (CoA, 10 April 2024) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 501 384 | Mentioned in the analysis (role not qualified) Also mentioned in 4 other decision(s): Novartis v ZENTIVA PORTUGAL (CFI, 31 July 2025) · STADAPHARM v ACCORD HEALTHCARE (CoA, 14 April 2025) · Accord Healthcare v Novartis (CFI, 10 April 2025) · ZENTIVA K.S. v NOVARTIS (CFI, 21 March 2025) | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.